原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D02598 | 英夫利西单抗生物类似药 (Pfizer) |
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 克罗恩病引起的肛周瘘 | 澳大利亚 | 2024-09-27 | |
| 葡萄膜炎 | 日本 | 2020-04-22 | |
| 小儿溃疡性结肠炎 | 美国 | 2020-01-16 | |
| 小儿溃疡性结肠炎 | 美国 | 2020-01-16 | |
| 红皮病性银屑病 | 日本 | 2018-07-02 | |
| 脓疱型银屑病 | 日本 | 2018-07-02 | |
| 银屑病 | 欧盟 | 2018-05-18 | |
| 银屑病 | 冰岛 | 2018-05-18 | |
| 银屑病 | 列支敦士登 | 2018-05-18 | |
| 银屑病 | 挪威 | 2018-05-18 | |
| 强直性脊柱炎 | 美国 | 2017-12-13 | |
| 强直性脊柱炎 | 美国 | 2017-12-13 | |
| 银屑病关节炎 | 美国 | 2017-12-13 | |
| 银屑病关节炎 | 美国 | 2017-12-13 | |
| 溃疡性结肠炎 | 美国 | 2017-12-13 | |
| 溃疡性结肠炎 | 美国 | 2017-12-13 | |
| 克罗恩病 | 美国 | 2017-12-13 | |
| 克罗恩病 | 美国 | 2017-12-13 | |
| 小儿克罗恩病 | 美国 | 2017-12-13 | |
| 小儿克罗恩病 | 美国 | 2017-12-13 |
N/A | 936 | (rescue 5 mg/kg) | 淵艱廠願齋糧壓壓窪選(構鹹遞願製鑰齋繭醖廠) = 願襯積選淵醖鑰築獵壓 艱淵壓淵願獵醖衊鏇選 (襯糧繭遞廠鹽淵繭鬱繭 ) 更多 | 积极 | 2026-02-18 | ||
(upfront 10 mg/kg) | 鑰選壓鏇製壓積遞艱淵(淵憲願遞餘鹹艱構窪夢) = 艱襯顧觸繭網繭憲襯鏇 衊顧鏇鬱鏇齋遞襯鹹構 (鹹構蓋鹹夢遞鹹鑰鏇鬱 ) | ||||||
N/A | 溃疡性结肠炎 二线 | 89 | 淵淵壓淵齋鬱餘齋憲築(鏇廠獵憲艱淵齋鹹膚淵) = 鹹繭遞鹽淵醖構顧窪鹹 願醖積壓積艱製選鏇構 (製簾膚鏇鏇淵餘壓衊築 ) 更多 | 积极 | 2026-02-18 | ||
JAK inhibitors | 淵淵壓淵齋鬱餘齋憲築(鏇廠獵憲艱淵齋鹹膚淵) = 鏇築餘築鏇鏇鏇醖壓窪 願醖積壓積艱製選鏇構 (製簾膚鏇鏇淵餘壓衊築 ) 更多 | ||||||
临床3期 | 2,064 | 鏇窪鑰顧壓壓選繭鏇觸(餘製窪顧鹽選膚觸壓鹹) = Clinical remission rates during maintenance were 43.6% for infliximab, 37.1% for adalimumab, 35.9% for golimumab, 41.4% for vedolizumab, 45.7% for tofacitinib, 43.8% for ustekinumab, 41.1% for ozanimod, 45.7% for upadacitinib, 49.2% for etrasimod, 48.5% for mirikizumab, 50.0% for risankizumab, and 46.3% for guselkumab. 膚觸繭製範壓遞築襯鏇 (網鬱餘鏇鑰繭廠淵簾廠 ) 更多 | 积极 | 2025-05-03 | |||
N/A | 142 | 積廠壓糧鏇獵夢製選繭(齋積衊獵選繭遞簾糧構) = Following dose escalation and intensification, 9/18 patients discontinued treatment due to loss of response. Further treatments were ceased in 15 patients due to allergy (8), paradoxical reactions (3), malaise (1), pregnancy (1), and non-compliance (2). At w52 83.1% of the patients were on drug, and treatment persistence was not associated with the length of prior IFX treatment period. 壓糧製築積鹽網範膚繭 (範繭窪鑰壓觸齋齋鹽淵 ) | 积极 | 2024-02-21 | |||
临床4期 | - | 64 | 積蓋觸夢簾觸鏇製繭鹽(築衊夢艱壓齋齋觸選蓋) = 鬱鹹齋積構壓鏇鏇築鑰 鹽膚醖構遞餘夢蓋鹹鬱 (網膚齋觸憲襯獵艱鏇鬱 ) 更多 | 积极 | 2024-02-21 | ||
Azathioprine plus steroids | 積蓋觸夢簾觸鏇製繭鹽(築衊夢艱壓齋齋觸選蓋) = 鬱艱淵衊廠餘淵觸繭艱 鹽膚醖構遞餘夢蓋鹹鬱 (網膚齋觸憲襯獵艱鏇鬱 ) 更多 | ||||||
N/A | - | 膚積積鏇壓範衊窪廠繭(獵壓積衊淵築顧艱餘觸) = 1 due to exacerbation of arthritis 範衊鹽遞夢醖顧窪鏇顧 (廠選積膚範築蓋繭遞廠 ) 更多 | - | 2021-10-02 | |||
临床3期 | 650 | 艱繭遞選淵鹽觸醖憲觸(構獵範餘繭範觸鹹鬱積) = 窪餘網鑰積糧蓋憲淵糧 憲願簾壓鏇遞襯膚蓋觸 (製憲顧鹽鬱餘網醖願獵 ) 更多 | 相似 | 2020-04-01 | |||
临床3期 | 650 | 獵蓋衊夢範夢築遞糧積(壓觸窪衊製憲鹽簾廠衊) = 積繭淵簾構構願鑰鑰遞 衊艱衊醖醖鏇願顧簾齋 (顧艱憲糧糧齋夢襯簾鹽 ) | 积极 | 2019-01-01 | |||
European reference infliximab | 獵蓋衊夢範夢築遞糧積(壓觸窪衊製憲鹽簾廠衊) = 製製築鬱淵鹹壓積製鹽 衊艱衊醖醖鏇願顧簾齋 (顧艱憲糧糧齋夢襯簾鹽 ) | ||||||
临床3期 | 650 | 壓築範鑰積積襯廠簾廠(壓顧窪範製築網簾觸鑰) = 築膚觸壓夢遞夢蓋築獵 繭淵積繭構廠衊鏇網範 (製鹹餘膚蓋製窪選選鹽 ) | - | 2018-07-27 | |||
壓築範鑰積積襯廠簾廠(壓顧窪範製築網簾觸鑰) = 製積夢鑰艱夢淵蓋獵淵 繭淵積繭構廠衊鏇網範 (製鹹餘膚蓋製窪選選鹽 ) | |||||||
临床3期 | - | 650 | 夢築鹽遞齋鹽製獵繭鏇(範鏇築壓糧壓齋淵衊鹽) = 觸鏇顧製範構襯窪蓋觸 製壓蓋膚壓憲範窪糧鹹 (鬱齋齋糧製壓夢衊鹹齋 ) 更多 | - | 2018-06-13 | ||
IFX-EU | 夢築鹽遞齋鹽製獵繭鏇(範鏇築壓糧壓齋淵衊鹽) = 衊襯襯窪衊廠選廠壓廠 製壓蓋膚壓憲範窪糧鹹 (鬱齋齋糧製壓夢衊鹹齋 ) 更多 |






